Showing results (271-280 of 345) with videos related to
Sort By:
Pageof 35
The Lancet. Infectious Diseases|January 1, 2016
Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trialXavier Sáez-Llorens, Ralf Clemens, Geert Leroux-Roels, et al.Letters in Applied Microbiology|September 4, 2020
Multi-drug resistant, biofilm-producing high-risk clonal lineage of Klebsiella in companion and household animalsA Banerjee, K Batabyal, A D Singh, et al.Journal of Biomedical Materials Research. Part A|March 26, 2010
Osteoconductivity of modified fluorcanasite glass-ceramics for bone tissue augmentation and repairS Bandyopadhyay-Ghosh, P E P Faria, A Johnson, et al.Proceedings of the National Academy of Sciences of the United States of America|May 5, 2005
Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulatorA Lippa, P Czobor, J Stark, et al.Mucosal Immunology|July 9, 2021
Mucosal immunity to poliovirusRuth I Connor, Elizabeth B Brickley, Wendy F Wieland-Alter, et al.The New England Journal of Medicine|August 30, 2018
Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral VaccineIsobel M Blake, Margarita Pons-Salort, Natalie A Molodecky, et al.The Journal of Physical Chemistry Letters|November 12, 2025
Green and Selective Oxidation of Benzyl Alcohol to Benzaldehyde over Transition Metal LDH Nanosheets: Combining Experiments and DFT CalculationsSeyedsaeed Mehrabi-Kalajahi, Seyed Amir Hossein Vasigh, Xin-Zhao Wu, et al.Letters in Applied Microbiology|May 16, 2019
Characterization of beta-lactamase and biofilm producing Enterobacteriaceae isolated from organized and backyard farm ducksA Banerjee, R Bardhan, M Chowdhury, et al.Letters in Applied Microbiology|October 7, 2021
Comparative occurrence of ESBL/AmpC beta-lactamase-producing Escherichia coli and Salmonella in contract farm and backyard broilersM Chowdhury, R Bardhan, S Pal, et al.Vaccine|April 30, 2017
Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin AmericaEduardo Lopez-Medina, Mario Melgar, James T Gaensbauer, et al.Pageof 35